medigraphic.com

2018, Número 2

<< Anterior Siguiente >>

Rev Med MD 2018; 9.10 (2)


Manifestaciones gastrointestinales en Diabetes Mellitus y factores asociados

Sánchez-Maza YDJ, Meixueiro-Daza A, García-Zermeño KR, Remes- Troche JM

Idioma: Español
Referencias bibliográficas: 53
Paginas: 185-190
Archivo PDF: 592.80 Kb.


RESUMEN

La Diabetes Mellitus representa una enfermedad que afecta a un gran grupo de personas. Altera prácticamente a todos los sistemas y el grado de afectación depende de la duración y gravedad de la enfermedad, así como otras comorbilidades. La afectación gastrointestinal puede presentarse como dismotilidad esofágica, enfermedad por reflujo gastroesofágico, gastroparesia, enteropatía, enfermedad hepática grasa no alcohólica y neoplasias gastrointestinales. El manejo óptimo de las complicaciones gastrointestinales es importante para el control metabólico apropiado de la diabetes y la mejora en la calidad de vida del paciente. Esta revisión es una actualización de las complicaciones gastrointestinales presentes en pacientes con Diabetes Mellitus con la finalidad de realizar un diagnóstico rápido, oportuno y de esta manera brindar un tratamiento adecuado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels, Belgium: International Diabetes Federation; 2017

  2. Maleki D, Locke GR III, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000; 160: 2808-16.

  3. Bytzer P, Talley NJ, Jones MP, et al. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther 2001; 15(1): 137-42.

  4. Nelson R, Shlossman M, Budding L, et al. Periodontal disease and NIDDM in Pima Indians. Diabetes Care. 1990;13:836–840.

  5. Javed F, Ahmed H, Mehmood A, et al. Association between glycemic status and oral Candida carriage in patients with prediabetes. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(1):53–58.

  6. Tsai C, Hayes C, Taylor G. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol. 2002;30:182–192.

  7. Al-Khabbaz AK. Type 2 diabetes mellitus and periodontal disease severity. Oral Health Prev Dent. 2014;12:77–82.

  8. Wang X, Han X, Guo X, Luo X, Wang D. The effect of periodontal treatment on hemoglobin a1c levels of diabetic patients: A systematic review and metaanalysis. PloS One. 2014;9(9):108412.

  9. Gustafsson RJ, Littorin B, Berntorp K, Frid A, Thorsson O, Olsson R, Ekberg O, Ohlsson B. Esophageal dysmotility is more common than gastroparesis in diabetes mellitus and is associated with retinopathy. Rev Diabet Stud 2011; 8: 268-27

  10. Wang X, Pitchumoni CS, Chandrarana K, Shah N. Increased prevalence of symptoms of gastroesophageal reflux diseases in type 2 diabetics with neuropathy. World J Gastroenterol 2008; 14: 709-712. Referencias bibliográficas

  11. Lee SD, Keum B, Chun HJ, Bak YT. Gastroesophageal Reflux Disease in Type II Diabetes Mellitus With or Without Peripheral Neuropathy. J Neurogastroenterol Motil 2011; 17:274-278.

  12. Białecka M, Niedzwiecki P, Ziółkiewicz DZ, Wierusz-Wysocka B. Tonsillectomy due to chronic tonsillitis improves metabolic control in type 1 diabetic patients. Clin Diabetes. 2013;2(6):208–212.

  13. Lin SW, Freedman ND, Hollenbeck AR, et al. Prospective study of selfreported diabetes and risk of upper gastrointestinal cancers. Cancer Epidemiol Biomarkers Prev. 2011;20:954–961. 20. Hasler WL. Gastroparesis. Curr Opin Gastroenterol 2012; 28:621-628.

  14. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-1 receptors in cancer and other disease. Arch Physiol Biochem. 2008;114:23–37.

  15. Dixon JL, Copeland LA, Zeber JE, et al. Association between diabetes and esophageal cancer, independent of obesity, in the United States veterans affairs population. Dis Esophagus. 2015. doi:10.1111/dote.12402.

  16. Chang CT, Shiau YC, Lin CC, Li TC, Lee CC, Kao CH. Improvement of esophageal and gastric motility after 2-week treatment of oral erythromycin in patients with non-insulindependent diabetes mellitus. J Diabetes Complications 2003;17: 141-144.

  17. Mearin F, Malagelada JR. Gastroparesis and dyspepsia in patients with diabetes mellitus. Eur J Gastroenterol Hepatol. 1995;7(8):717–723.

  18. Bharucha AE, Kudva Y, Basu A, et al. Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. Clin Gastroenterol Hepatol. 2015;13:466–476.

  19. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24: 371-381.

  20. Hasler WL. Gastroparesis. Curr Opin Gastroenterol 2012; 28:621-628.

  21. Ordög T, Takayama I, Cheung WK, Ward SM, Sanders KM. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 2000; 49: 1731-1739.

  22. Grover M, Farrugia G, Lurken MS, Bernard CE, Faussone- Pellegrini MS, et al. Celular changes in diabetic and idiopathic gastroparesis. Gastroenterology 2011; 140: 1575-1585.e8.

  23. Selim MM, Wendelschafer-Crabb G, Redmon JB, Khoruts A, Hodges JS, et al. Gastric mucosal nerve density: a biomarker for diabetic autonomic neuropathy? Neurology 2010; 75: 973-981.

  24. Parkman HP, Yates K, Hasler WL, Nguyen L, Pasricha PJ, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 2011; 9: 1056-1064.

  25. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127:1592-1622

  26. Tougas G, Chen Y, Coates G, Paterson W, et al. Standardization of a simplified scintigraphic methodology for the assessment of gastric emptying in a multicenter setting. Am J Gastroenterol 2000;95:78-86.

  27. Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008; 103: 753-763.

  28. Lee A, Wilding G, Kuo B. Variable abnormal physiological motility in the proximal upper gastrointestinal tracting astroparesis. Neurogastroenterol Motil 2012; 24: 652-657, e276.

  29. Perri F, Bellini M, Portincasa P, Parodi A, Bonazzi P, et al. (13)C-octanoic acid breath test (OBT) with an ewtes tmeal (EXPIRO Ger):To ward standardization for testing gastric emptying of solids. Dig Liver Dis 2010; 42: 549-553.

  30. Barshop K, Staller K, Semler J, Kuo B. Duodenal rather than antral motility contractile parameters correlate with symptom severity in gastroparesis patients. Neurogastroenterol Motil. 2015;27:339–346.

  31. Asakawa A, Ueno N, Katagi M, Ijuin Y, Morita Y, et al. Mosapride improves food intake, while not worsening glycemic control and obesity, in ob/ob obese mice with decreased gastric emptying. J Diabetes Complications 2006; 20: 56-58

  32. Mondal A, Xie Z, Miyano Y, Tsutsui C, Sakata I, et al. Coordination of motilin and ghrelin regulates the migrating motor complex of gastrointestinal motility in Suncus murinus. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1207-G1215.

  33. Wo JM, Ejskjaer N, Hellström PM, Malik RA, Pezzullo JC, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting-randomised clinical study subset data. Aliment Pharmacol Ther 2011; 33: 679-688.

  34. Rodriguez L, Rosen R, Manfredi M, Nurko S. Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study. Gastrointest Endosc 2012; 75: 302-309.

  35. McCallum RW, Lin Z, Forster J, Roeser K, Hou Q, Sarosiek I. Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years. Clin Gastroenterol Hepatol 2011; 9: 314-319.e1.

  36. Deb S, Tang SJ, Abell TL, Rao S, Huang WD, T et al. An endoscopic wireless gastrostimulator (with video). Gastrointest Endosc 2012; 75: 411-415, 415.el

  37. Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol 1996; 91: 2174-2178.

  38. Phillips LK, Rayner CK, Jones KL, Horowitz M. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep 2006; 6: 417-423.

  39. Chandrasekharan B, Anitha M, Blatt R, Shahnavaz N, Kooby D, et al. Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol Motil 2011; 23: 131-138, e26.

  40. Lee TH, Lee JS. Ramosetron might be useful for treating diabetic diarrhea with a rapid small bowel transit time. Korean J Intern Med 2013; 28: 106-107.

  41. Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol 1999; 94: 2165-2170.

  42. Ohlsson B, Melander O, Thorsson O, Olsson R, Ekberg O, Sundkvist G. Oesophageal dysmotility, delayed gastric emptying and autonomic neuropathy correlate to disturbed glucose homeostasis. Diabetologia 2006; 49: 2010-2014.

  43. 43.Russo A, Botten R, Kong MF, Chapman IM, Fraser RJ, Horowitz M, Sun WM. Effects of acute hyperglycaemia on anorectal motor and sensory function in diabetes mellitus. Diabet Med 2004; 21: 176-182.

  44. Virally-Monod M, Tielmans D, Kevorkian JP, Bouhnik Y, Flourie B, et al. Chronic diarrhea and diabetes mellitus: prevalence of small intestinal bacterial overgrowth.Diabet Metab 1998;24:530-536

  45. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity--a review. Chemotherapy 2005; 51 Suppl 1: 67-72.

  46. Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005; 3: 201-211.

  47. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 2009; 18: 349-358.

  48. King RJ, Harrison L, Gilbey SG, et al. Diabetic hepatosclerosis: Another diabetes microvascular complication? Diabet Med. 2016;33(2):5–7.

  49. Hudacko RM, Sciancalepore JP, Fyfe BS. Diabetic microangiopathy in the liver: An autopsy study of incidence and association with other diabetic complications. Am J Clin Pathol. 2009;132:494–499.

  50. Naing CMJ, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: Meta-analysis. World J Gastroenterol. 2012;18:1642–1651

  51. Lecube A, Hernández C, Genesca J, Simó R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic HCV patients: A casecontrol study. Diabetes Care. 2006;29:1096–1101.

  52. del Campo JA, García-Valdecasas M, Rojas L, Rojas A, Romero- Gómez M. The HCV modulates insulin signaling pathway in vitro promoting insulin resistance. PLoS One.2012;7:47904.

  53. Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients type 2 diabetic patients. Diabetes Care. 2010;33:1997–2003.




2020     |     www.medigraphic.com